Table 4. Univariate and multivariate Cox regression analyses for PFS and OS in patients with castration-resistant prostate cancer treated with abiraterone.
| Univariate Analysis | PFS Risk from Baseline | OS Risk from Baseline | ||||
|---|---|---|---|---|---|---|
| Parameters | HR | 95% CI | P | HR | 95% CI | P |
| Gleason score (8–9 vs 6–7) | 1.0 | 0.5 – 2.2 | 0.985 | 1.8 | 0.6 – 5.3 | 0.273 |
| No. previous chemotherapeutic regimens (>2 vs 1) | 1.8 | 0.8 – 3.8 | 0.126 | 2.4 | 0.9 – 6.7 | 0.088 |
| PSA decline (<50% vs >50%) |
3.6 | 1.6 – 7.9 | 0.002 | 3.3 | 1.2 – 9.2 | 0.022 |
| FCH-PET/CT (SD/PD vs CR/PR) |
3.1 | 1.3 – 7.4 | 0.009 | 2.8 | 0.9 – 8.8 | 0.078 |
| FCH-PET/CT (PD vs CR/PR/SD) |
6.8 | 2.7 – 17.5 | <0.0001 | 5.3 | 1.8 – 15.1 | 0.002 |
| Multivariate Analysis | PFS Analysis | OS Analysis | ||||
|---|---|---|---|---|---|---|
| Parameters | HR | 95% CI | P | HR | 95% CI | P |
| PSA decline (<50% vs >50%) |
2.0 | 0.8 – 8.1 | 0.134 | 1.4 | 0.4 – 5.1 | 0.568 |
| FCH-PET/CT (SD/PD vs CR/PR) |
1.3 | 0.4 – 4.2 | 0.623 | |||
| FCH-PET/CT (PD vs CR/PR/SD) |
4.1 | 1.2 – 14.0 | 0.022 | 4.3 | 1.2 – 15.4 | 0.027 |
PFS = progression-free survival; OS = overall survival; HR = hazard ratio; CI = confidence interval; SD = stable disease; PD = progressive disease; CR = complete response; PR = partial remission.